Anti-Human CD194 (CCR4) (Mogamulizumab) - Biotin
Catalogue Number: 12-8020-ABO
| Manufacturer: | Abeomics |
| Type: | Recombinant Monoclonal |
| Alias: | CD194; CKR-4; CCR-4; CCR4; K5-5 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug |
| Host name: | Human |
| Clone: | KW-0761 |
| Isotype: | IgG1, kappa |
| Immunogen: | Humanization of mouse anti-CCR4 mAb7. |
| Application: | ELISA |
Description
Description: Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only. Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1-infected cells and the levels of inflammatory markers related to HTLV-1-Associated Myelopathy.3
Additional Text
Antibody Clonality
Monoclonal
Application Notes
The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.ELISA
12-8020 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations